Tags

Type your tag names separated by a space and hit enter

From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
Pediatr Nephrol. 2016 Feb; 31(2):195-206.PN

Abstract

Canonical Wnt signaling activity contributes to physiological and adaptive bone mineralization and is an essential player in bone remodeling. Sclerostin is a prototypic soluble canonical Wnt signaling pathway inhibitor that is produced in osteocytes and blocks osteoblast differentiation and function. Therefore, sclerostin is a potent inhibitor of bone formation and mineralization. Accordingly, rodent sclerostin-deficiency models exhibit a strong bone phenotype. Moreover, blocking sclerostin represents a promising treatment perspective against osteoporosis. Beyond the bone field novel data definitely associate Wnt signaling in general and sclerostin in particular with ectopic extraosseous mineralization processes, as is evident in cardiovascular calcification or calciphylaxis. Uremia is characterized by parallel occurrence of disordered bone mineralization and accelerated cardiovascular calcification (chronic kidney disease - mineral and bone disorder, CKD-MBD), linking skeletal and cardiovascular disease-the so-called bone-vascular calcification paradox. In consequence, sclerostin may qualify as an emerging player in CKD-MBD. We present a stepwise review approach regarding the rapidly evolving field sclerostin participation in CKD-MBD. Starting from data originating in the classical bone field we look separately at three major areas of CKD-MBD: disturbed mineral metabolism, renal osteodystrophy, and uremic cardiovascular disease. Our review is intended to help the nephrologist revise the potential importance of sclerostin in CKD by focusing on how sclerostin research is gradually evolving from the classical osteoporosis niche into the area of CKD-MBD. In particular, we integrate the limited amount of available data in the context of pediatric nephrology.

Authors+Show Affiliations

Department of Cardiology, University Hospital of the RWTH Aachen, Pauwelsstraβe 30, 52057, Aachen, Germany. vincent.brandenburg@post.rwth-aachen.de.Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.Department of Cardiology, University Hospital of the RWTH Aachen, Pauwelsstraβe 30, 52057, Aachen, Germany.Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium.Department of Immunology and Microbiology, Laboratory of Nephrology, University Hospitals Leuven, Leuven, Belgium.Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.Department of Immunology and Microbiology, Laboratory of Nephrology, University Hospitals Leuven, Leuven, Belgium.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25735207

Citation

Brandenburg, Vincent M., et al. "From Skeletal to Cardiovascular Disease in 12 Steps-the Evolution of Sclerostin as a Major Player in CKD-MBD." Pediatric Nephrology (Berlin, Germany), vol. 31, no. 2, 2016, pp. 195-206.
Brandenburg VM, D'Haese P, Deck A, et al. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol. 2016;31(2):195-206.
Brandenburg, V. M., D'Haese, P., Deck, A., Mekahli, D., Meijers, B., Neven, E., & Evenepoel, P. (2016). From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatric Nephrology (Berlin, Germany), 31(2), 195-206. https://doi.org/10.1007/s00467-015-3069-7
Brandenburg VM, et al. From Skeletal to Cardiovascular Disease in 12 Steps-the Evolution of Sclerostin as a Major Player in CKD-MBD. Pediatr Nephrol. 2016;31(2):195-206. PubMed PMID: 25735207.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. AU - Brandenburg,Vincent M, AU - D'Haese,Patrick, AU - Deck,Annika, AU - Mekahli,Djalila, AU - Meijers,Björn, AU - Neven,Ellen, AU - Evenepoel,Pieter, Y1 - 2015/03/04/ PY - 2014/10/12/received PY - 2015/02/09/accepted PY - 2015/01/26/revised PY - 2015/3/5/entrez PY - 2015/3/5/pubmed PY - 2016/9/23/medline KW - Bone mineralization KW - Cardiovascular calcification KW - Chronic kidney disease mineral and bone disorder KW - Sclerostin KW - Wnt signaling SP - 195 EP - 206 JF - Pediatric nephrology (Berlin, Germany) JO - Pediatr Nephrol VL - 31 IS - 2 N2 - Canonical Wnt signaling activity contributes to physiological and adaptive bone mineralization and is an essential player in bone remodeling. Sclerostin is a prototypic soluble canonical Wnt signaling pathway inhibitor that is produced in osteocytes and blocks osteoblast differentiation and function. Therefore, sclerostin is a potent inhibitor of bone formation and mineralization. Accordingly, rodent sclerostin-deficiency models exhibit a strong bone phenotype. Moreover, blocking sclerostin represents a promising treatment perspective against osteoporosis. Beyond the bone field novel data definitely associate Wnt signaling in general and sclerostin in particular with ectopic extraosseous mineralization processes, as is evident in cardiovascular calcification or calciphylaxis. Uremia is characterized by parallel occurrence of disordered bone mineralization and accelerated cardiovascular calcification (chronic kidney disease - mineral and bone disorder, CKD-MBD), linking skeletal and cardiovascular disease-the so-called bone-vascular calcification paradox. In consequence, sclerostin may qualify as an emerging player in CKD-MBD. We present a stepwise review approach regarding the rapidly evolving field sclerostin participation in CKD-MBD. Starting from data originating in the classical bone field we look separately at three major areas of CKD-MBD: disturbed mineral metabolism, renal osteodystrophy, and uremic cardiovascular disease. Our review is intended to help the nephrologist revise the potential importance of sclerostin in CKD by focusing on how sclerostin research is gradually evolving from the classical osteoporosis niche into the area of CKD-MBD. In particular, we integrate the limited amount of available data in the context of pediatric nephrology. SN - 1432-198X UR - https://www.unboundmedicine.com/medline/citation/25735207/From_skeletal_to_cardiovascular_disease_in_12_steps_the_evolution_of_sclerostin_as_a_major_player_in_CKD_MBD_ L2 - https://dx.doi.org/10.1007/s00467-015-3069-7 DB - PRIME DP - Unbound Medicine ER -